Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
CAMBRIDGE, Mass., Feb. 27, 2017 -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that management will participate in two upcoming investor conferences in March. Details of the presentations are as follows:
| Cowen & Company 37th Annual Healthcare Conference | |||
| Date: | Monday, March 6, 2017 | ||
| Time: | 2:40 p.m. ET | ||
| Location: | Boston | ||
| Barclays Global Healthcare Conference 2017 | |||
| Date: | Thursday, March 16, 2017 | ||
| Time: | 9:30 a.m. ET | ||
| Location: | Miami | ||
Live webcasts of the presentations will be available on the Investors & Media section of the Editas website at www.editasmedicine.com. Archived replays will be available for approximately 30 days following the respective presentations.
About Editas Medicine
Editas Medicine is a leading genome editing company dedicated to treating patients with genetically-defined diseases by correcting their disease-causing genes. The company was founded by world leaders in genome editing, and its mission is to translate the promise of genome editing science into a broad class of transformative genomic medicines to benefit the greatest number of patients.
Media Contact Dan Budwick Pure Communications, Inc. (973) 271-6085 [email protected] Investor Contact Mark Mullikin Editas Medicine, Inc. (617) 401-9083 [email protected]
